Journal
CLINICAL & EXPERIMENTAL METASTASIS
Volume 34, Issue 8, Pages 443-447Publisher
SPRINGER
DOI: 10.1007/s10585-017-9872-8
Keywords
Neoadjuvant chemotherapy; Relapse; Metastatic progression; Survival
Categories
Funding
- BLRD VA [I01 BX003374] Funding Source: Medline
Ask authors/readers for more resources
This commentary was written as a collaboration between the Board of the Metastasis Research Society and two patients with metastatic breast cancer. It was conceived in response to how preclinical scientific research is sometimes presented to non-scientists in a way that can cause stress and confusion. Translation of preclinical findings to the clinic requires overcoming multiple barriers. This is irrespective of whether the findings relate to exciting responses to new therapies or problematic effects of currently used therapies. It is important that these barriers are understood and acknowledged when research findings are summarized for mainstream reporting. To minimize confusion, patients should continue to rely on their oncology care team to help them interpret whether research findings presented in mainstream media have relevance for their individual care. Researchers, both bench and clinical, should work together where possible to increase options for patients with metastatic disease, which is still in desperate need of effective therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available